Professor Łukaszuk about the role of biomarkers and comprehensive diagnostics in the assessment of female fertility

Professor Łukaszuk about the role of biomarkers and comprehensive diagnostics in the assessment of female fertility

During one of the major conferences for specialists in gynecology and obstetrics – The All-Poland Congress ‘Our Gynecology” in Warsaw – Professor Krzysztof Łukaszuk, Head of INVICTA Fertility Clinics, discussed the most recent trends in the assessment of female fertility, with special regard to the role of biomarkers and comprehensive diagnostics of female infertility. Both the high attendance at the lecture and questions reported after the presentation are the proof that the needs of the congress’s participants in this area were targeted accurately.

Fertility disorders occur in nearly every 5th couple trying for a child. In almost half of the cases, difficulties with conceiving a child are related to the abnormalities in the functioning of the woman’s body. Therefore the comprehensive assessment of female fertility represents a significant challenge in modern gynecology.

During his lecture, Professor Łukaszuk discussed broadly the possibility of the clinical implementation of AMH parameter that is applied on an increasing basis in assisted reproductive medicine – both at the stage of ovarian reserve evaluation in women and in the course of personalized treatment using the in vitro fertilization method.

The INVICTA expert paid also particular attention to the importance of genetic diagnosis. Among the most important conclusions from the lecture, in the first place the following should be emphasized:

  • the possibility to apply the determination of AMH level in the prediction of procreative chances and treatment planning – in particular in women with low ovarian reserve and of mature age (35+)
  • recommendation to carry out karyotype tests in both partners trying for a child with the aim to assess the potential genetic risk
  • taking into account the tests for genetic mutations associated with the increased risk of recurrent miscarriages in women in diagnostics preceding the treatment
  • • use of preimplantation tests in IVF treatment in women over the age of 35 and experiencing recurrent miscarriages, as the factor that significantly increases the efficacy of treatment and the rate of healthy live-born babies.

See a short photo coverage of the conference:

INVICTA Genetic Laboratory has been performing genetic screening of embryos since 2005. Our team of world-class experts and scientists has been developing the innovative methods of preimplantation genetic diagnosis (PGD) for over 13 years.